Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Seonix Bio
San Diego, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
SightScore is a clinically validated polygenic risk score test for glaucoma that analyzes over 7 million genetic variants using a saliva sample. It has demonstrated predictive value for glaucoma onset, progression, and need for treatment or surgery, with validation published in Nature Genetics and JAMA Ophthalmology. The tool helps clinicians prioritize and personalize management of patients at risk for glaucoma
- Therapeutic areas
- Ophthalmology
- Modalities
- Genetic testingPolygenic risk score
- Industry
- Molecular Diagnostics
Beyond the preview
Go deeper on Seonix Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Seonix Bio.